News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Assessment of Predisposition Genes in High-Grade Serous Ovarian Carcinoma via Germline and Tumour Sequencing
Ovarian Cancer
Feb 5, 2025, 07:02

Assessment of Predisposition Genes in High-Grade Serous Ovarian Carcinoma via Germline and Tumour Sequencing

Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on X:

“New study identifies key genes in ovarian cancer risk

PALB2 and ATM confirmed as predisposition genes

LLGL2 emerges as a novel candidate Other proposed genes fail validation

Integrating tumor sequencing is crucial!!”

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing | npj Genomic Medicine

Authors: Deepak N. Subramanian, Maia Zethoven, Kathleen I. Pishas, Evanny R. Marinović, Simone McInerny, Simone M. Rowley, Prue E. Allan, Lisa Devereux, Dane Cheasley, Paul A. James and Ian G. Campbell

Assessment of Predisposition Genes in High-Grade Serous Ovarian Carcinoma via Germline and Tumour Sequencing

cancer Dane Cheasley Deepak N. Subramanian Elvina Almuradova Evanny R. Marinović Ian G. Campbell Kathleen I. Pishas Lisa Devereux Maia Zethoven OncoDaily Oncology Paul A. James Prue E. Allan Simone M. Rowley Simone McInerny
Special Coverage
Blog
Feb 5, 2025, 07:02
Assessment of Predisposition Genes in High-Grade Serous Ovarian Carcinoma via Germline and Tumour Sequencing
Insight
Feb 5, 2025, 06:53
Lauro Gregianin: Results of the GALOP-2011 Trial for Patients With Localized Ewing Sarcoma
Blog
Feb 5, 2025, 06:47
Earle Burgess: Results from the ENZADA trial for men with advanced prostate cancer
Blog
Feb 5, 2025, 05:59
Wafik El-Deiry: Robert F. Kennedy Jr's plans for health reform
Science
Feb 5, 2025, 05:42
Management of adverse events in patients receiving Tarlatamab for previously treated SCLC by Jacob Sands et al.
Blog
Feb 5, 2025, 00:16
Celebrating Ben Anderson’s Retirement and the Next Phase of Cancer Care Innovation at C/Can
Blog
Feb 5, 2025, 00:14
Joanna Strober: A breakthrough moment for women's healthcare
Blog
Feb 5, 2025, 00:12
Don't miss the opportunity to join the ESO Improving Cancer Outcomes and Leadership course
Blog
Feb 5, 2025, 00:10
Noelene Kotschan: Join Pink Drive in the fight against cancer
Blog
Feb 5, 2025, 00:08
City Cancer Challenge - Where you live and who you are shouldn’t determine the quality of cancer care you receive
Blog
Feb 5, 2025, 00:06
Chris Boshoff: Pfizer’s BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Phase 3 BREAKWATER Trial
Blog
Feb 5, 2025, 00:04
Sandra Demaria: Join Female Leaders in IO at the 7th Annual SITC WIN Leadership Institute